Bredt David 4

What Happened David Bredt, Chief Scientific Officer of Rapport Therapeutics (RAPP), was granted a derivative award on Feb 2, 2026 covering 103,000 shares (transaction code A). The Form 4 reports an acquisition price of $0.00 for the derivative (no cash paid at grant). This is a compensation award (an option award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Amount: 103,000 shares reported as a derivative acquisition; reported price $0.00.
• Vesting/exercise: per footnote, the shares underlying this option vest and become exercisable in 48 equal monthly installments beginning Jan 1, 2026, subject to continued service.
• Shares owned after transaction: not specified in the filing.
• Transaction type: Award/grant of a derivative security (option); not a sale or open-market buy.

Context This is a standard equity compensation grant for an executive. As a derivative award, the shares are not immediately owned — they will only vest and become exercisable over time and upon any required exercise. There is no indication in this filing of an immediate sale or cashless exercise.